Epidemiology of Cryptococcal Meningitis in the US: 1997-2009

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Pyrgos, Vasilios ^a   Seitz, Amy E ^a   Steiner, Claudia A ^b   Prevots, D Rebecca ^a   Williamson, Peter R ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CELLULAR IMMUNODEFICIENCY; CHRONIC KIDNEY FAILURE; COMORBIDITY; CRYPTOCOCCAL MENINGITIS; CUSHING SYNDROME; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; FEMALE; HEALTH CARE QUALITY; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; HYDROCEPHALUS; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NONHUMAN; POPULATION RESEARCH; SEX RATIO; TREND STUDY; UNITED STATES;

COMORBIDITY; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; UNITED STATES;

EID: 84874078108     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056269     Document Type: Article

References (41)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids 23: 525-530.
2. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, et al. (2003) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 36: 789-794.
3. Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL, (2004) Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 53: 935-940.
4. Chayakulkeeree M, Perfect JR (2006) Cryptococcosis. Infect Dis Clin North Am 20: 507-544, v-vi.
5. Littman ML, Borok R, (1968) Relation of the pigeon to cryptococcosis: natural carrier state, heat resistance and survival of Cryptococcus neoformans. Mycopathol Mycol Appl 35: 329-345.
6. Kaufman L, Blumer S (1978) Cryptococcosis: the awakening giant; Washington DC. Pan American Health Organization Scientific Publication. 176-184.
7. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, et al. (1999) Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 179: 449-454.
8. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, et al. (2004) Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. Aids 18: 555-562.
9. Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C, et al. (2012) Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One 7: e43582.
10. Joshi NS, Fisher BT, Prasad PA, Zaoutis TE, (2010) Epidemiology of cryptococcal infection in hospitalized children. Pediatr Infect Dis J 29: e91-95.
11. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR, (2012) Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 185: 881-886.
12. Lindenauer PK, Lagu T, Shieh MS, Pekow PS, Rothberg MB, (2012) Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009. JAMA 307: 1405-1413.
13. Sickbert-Bennett EE, Weber DJ, Poole C, MacDonald PD, Maillard JM, (2010) Utility of International Classification of Diseases, Ninth Revision, Clinical Modification codes for communicable disease surveillance. Am J Epidemiol 172: 1299-1305.
14. Jiang HJ, Ciccone K, Urlaub CJ, Boyd D, Meeks G, et al. (2001) Adapting the HCUP QIs for hospital use: the experience in New York State. Jt Comm J Qual Improv 27: 200-215.
15. Park MK, Hospenthal DR, Bennett JE, (1999) Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clinical Infectious Diseases 28: 629-633.
16. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, et al. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33: 690-699.
17. Bonnet F, Lewden C, May T, Heripret L, Jougla E, et al. (2005) Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 37: 482-487.
18. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P, (2004) A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med 5: 140-143.
19. Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE, (2006) Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 42: 822-825.
20. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, et al. (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 31: 499-508.
21. Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA, et al. (2008) Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 27: 937-943.
22. Baumgardner DJ, Halsmer SE, Egan G, (2004) Symptoms of pulmonary blastomycosis: northern Wisconsin, United States. Wilderness Environ Med 15: 250-256.
23. Emmons CW, (1955) Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 62: 227-232.
24. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340: 764-771.
25. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50: 291-322.
26. Byrnes EJ, 3rd, Li W, Lewit Y, Perfect JR, Carter DA, et al (2009) First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One 4: e5851.
27. Battal B, Kocaoglu M, Bulakbasi N, Husmen G, Tuba Sanal H, et al. (2011) Cerebrospinal fluid flow imaging by using phase-contrast MR technique. Br J Radiol 84: 758-765.
28. Mangham D, Gerding DN, Peterson LR, Sarosi GA, (1983) Fungal meningitis manifesting as hydrocephalus. Arch Intern Med 143: 728-731.
29. Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV, (2004) Cryptococcus neoformans Infection in Patients With Cirrhosis, Including Liver Transplant Candidates. Medicine (Baltimore) 83: 188-192.
30. Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, et al. (2011) Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 53: 1188-1195.
31. Wyke RJ, Rajkovic IA, Eddleston AL, Williams R, (1980) Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut 21: 643-649.
32. Truelsen K, Young T, Kozel TR, (1992) In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect Immun 60: 3937-3939.
33. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE, (2007) Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 86: 78-92.
34. Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, et al. (2010) The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol 184: 5755-5767.
35. Mukherjee J, Pirofski LA, Scharff MD, Casadevall A, (1993) Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A 90: 3636-3640.
36. Rentz AM, Halpern MT, Bowden R, (1998) The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27: 781-788.
37. Fisher ES, Bynum JP, Skinner JS, (2009) Slowing the growth of health care costs-lessons from regional variation. N Engl J Med 360: 849-852.
38. Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, et al. (2008) Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol 29: 25-30.
39. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821.
40. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
41. Lui G, Lee N, Ip M, Choi KW, Tso YK, et al. (2006) Cryptococcosis in apparently immunocompetent patients. QJM 99: 143-151.